AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
By Sabela Ojea
Shares of AbbVie lost 4.6% to close at $159.62 on Friday after the company warned about the effects of losing the exclusivity of its patent for the arthritis medication Humira, the highest-grossing drug ever.
The drugmaker guided for second-quarter revenue of $14 billion, reflecting a step-up in volume erosion from Humira due to an increase in competition. The second and fourth quarter are usually known for having the highest levels of volume.
The North Chicago, Ill.-based company's full-year outlook is in line with its guidance at the beginning of the year, Chief Commercial Officer Jeffrey Ryan Stewart said on a call with analysts.
"We are not saying that volume is worse than we originally guided. We're saying this is tracking in line with our expectations," Chief Executive Robert Michael said.
In the first quarter, AbbVie reported a 36% drop in Humira-related revenue, driving a 3.9% decline in revenue coming from its immunology portfolio. Despite this, its quarterly topline performance rose from gains elsewhere and the company raised its annual adjusted earnings guidance.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 26, 2024 16:53 ET (20:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors
-
Occidental Earnings: CrownRock Transaction Should Still Close, but Not Until the Third Quarter
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?